9,686 results match your criteria Am. J. Hematol.[Journal]


Patient-reported Outcomes in Sickle Cell Disease and Association with Clinical and Psychosocial Factors: Report from the Sickle Cell Disease Implementation Consortium.

Am J Hematol 2020 May 25. Epub 2020 May 25.

University of California San Francisco Benioff Children's Hospital Oakland Sickle Cell Disease Implementation Consortium.

Understanding patient experiences, quality of life, and treatment needs in individuals with sickle cell disease (SCD) is essential in promoting health and well-being. We used measures from the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me), Patient Reported Outcomes Measurement Information System (PROMIS), and Quality of Life in Neurological Disorders (NeuroQol) to evaluate pain impact, sleep impact, social functioning, depressive symptoms, tiredness, and cognitive function [collectively, patient reported outcomes (PROs)] and to identify associated demographic and clinical characteristics. Participants (n=2201), between 18 and 45 years, were recruited through the eight Sickle Cell Disease Implementation Consortium (SCDIC) sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25880DOI Listing

Impact of detectable measurable residual disease on umbilical cord blood transplantation.

Am J Hematol 2020 May 25. Epub 2020 May 25.

EBMT Paris study office / CEREST-, TC, Paris, France.

The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. Inclusion criteria included adult patients with acute myeloid (AML) or acute lymphoblastic leukemia (ALL), CBT as first allo-HCT in first or second complete remission (CR) at transplantation, and known MRD status at the time of CBT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25879DOI Listing

Risk-based, Response-adapted Therapy for Early-stage Extranodal Nasal-type NK/T-cell Lymphoma in the Modern Chemotherapy Era: A China Lymphoma Collaborative Group (CLCG) Study.

Am J Hematol 2020 May 25. Epub 2020 May 25.

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.

We aimed to determine the survival benefits of chemotherapy (CT) additional to radiotherapy (RT) in different risk groups of patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL) and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new-regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT+CT), or CT followed by RT (CT+RT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25878DOI Listing
May 2020
3.798 Impact Factor

Immune Thrombocytopenia during Pregnancy due to COVID-19.

Am J Hematol 2020 May 23. Epub 2020 May 23.

Department of Clinical Hematology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25877DOI Listing

Real-World Effectiveness of Eliglustat in Treatment-Naïve and Switch Patients Enrolled in the International Collaborative Gaucher Group Gaucher Registry.

Am J Hematol 2020 May 21. Epub 2020 May 21.

Sanofi Genzyme, Cambridge, MA, USA.

Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6-metabolizer phenotypes (90% of patients). We report real-world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Registry (NCT00358943). As of January 2019, baseline and 2-year data (±1 year) were available for 231 eliglustat-treated GD1 patients: 19 treatment-naïve (0 splenectomized) and 212 ERT patients who switched to eliglustat (36 splenectomized). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25875DOI Listing

Disrupt, Innovate, and Transform in the Era of COVID-19.

Authors:
John Nosta

Am J Hematol 2020 May 19. Epub 2020 May 19.

NostaLab, 85 West Main Street, Mendham, New Jersey, 07945.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25866DOI Listing

Laboratory Misdiagnosis of von Willebrand Disease in Post-Menarchal Females: A Multi-Center Study.

Am J Hematol 2020 May 17. Epub 2020 May 17.

The Ohio State University College of Medicine.

Increased awareness of von Willebrand Disease (VWD) has led to more frequent diagnostic laboratory testing, which insurers often dictate be performed at a facility with off-site laboratory processing instead of a coagulation facility with onsite processing. Off-site processing is more prone to preanalytical variables causing falsely low levels of von Willebrand Factor (VWF) due to the additional transport required. Our aim was to determine the percentage of discordance between off-site and onsite specimen processing for VWD in this multicenter, retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25869DOI Listing

Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Division of Hematology, Blood & Marrow Transplantation, University of Kentucky Medical Center, Markey Cancer Center, Lexington.

Mixed phenotype acute leukemia (MPAL) is thought to have poor outcome, and presence of the Philadelphia chromosome (Ph+) has been considered to be an adverse prognostic marker. However, most of these reports were in the pre-tyrosine kinase inhibitors (TKIs) era. Recent limited reports indicate improved outcomes for MPAL with the addition of TKIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25873DOI Listing

ABVD vs BEACOPP escalated in Advanced-Stage Hodgkin's Lymphoma: results from a multicenter European study.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

The optimal first-line treatment for advanced-stage Hodgkin's lymphoma (HL) is still a matter of debate. While ABVD is less toxic and as effective as other more intensive chemotherapy regimens, escalated BEACOPP (BEACOPPesc) is superior to ABVD for initial disease control and prolonged time-to-relapse. However, this advantage is associated with higher rate of early and late toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25871DOI Listing
May 2020
3.798 Impact Factor

Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

Am J Hematol 2020 May 17. Epub 2020 May 17.

Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25870DOI Listing

"ITP" is not always immune thrombocytopenia.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Centre for Haematology, St Mary's Hospital campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, W2 1NY, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25872DOI Listing

The emergence of methemoglobinemia amidst the COVID-19 pandemic.

Am J Hematol 2020 May 15. Epub 2020 May 15.

Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25868DOI Listing

Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study.

Am J Hematol 2020 May 12. Epub 2020 May 12.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25864DOI Listing

Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.

Am J Hematol 2020 May 11. Epub 2020 May 11.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25857DOI Listing

Evidence of transfusion-induced reductions in cerebral capillary shunting in sickle cell disease.

Am J Hematol 2020 May 10. Epub 2020 May 10.

Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25863DOI Listing

Erratum.

Authors:

Am J Hematol 2020 Jun 20;95(6):730. Epub 2020 Apr 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25835DOI Listing

Erratum.

Authors:

Am J Hematol 2020 Jun 14;95(6):728. Epub 2020 Feb 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25745DOI Listing

Erratum.

Authors:

Am J Hematol 2020 Jun 15;95(6):729. Epub 2020 Mar 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25779DOI Listing

The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.

Am J Hematol 2020 May 10. Epub 2020 May 10.

Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy. Unfortunately, many of these patients relapse after HCT and have a limited survival. The recent approval of venetoclax, an orally bioavailable BCL-2 inhibitor, resulted in significant responses in treatment naïve acute myeloid leukemia (AML) and off-label use in the relapsed/refractory setting is increasing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25859DOI Listing

Schistocytosis is not always microangiopathic hemolytic anemia.

Am J Hematol 2020 May 10. Epub 2020 May 10.

Centre for Haematology, St Mary's Hospital campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25861DOI Listing

G6PD deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.

Am J Hematol 2020 May 10. Epub 2020 May 10.

Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25862DOI Listing

Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management.

Authors:
Stephen M Ansell

Am J Hematol 2020 May 8. Epub 2020 May 8.

Mayo Clinic, United States.

Disease Overview: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8,480 new patients annually and representing approximately 10% of all lymphomas in the United States.

Diagnosis: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25856DOI Listing

Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.

Am J Hematol 2020 Apr 30. Epub 2020 Apr 30.

Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25851DOI Listing

"Triple hit" SOX-11 , CD10 , TP53 mutated high-grade pleomorphic mantle cell lymphoma.

Am J Hematol 2020 May 1. Epub 2020 May 1.

Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25848DOI Listing

Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patient.

Am J Hematol 2020 May 1. Epub 2020 May 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25850DOI Listing
May 2020
3.798 Impact Factor

The Impact of Extended Half-Life Factor Concentrates on Prophylaxis for Severe Hemophilia in The United States.

Am J Hematol 2020 Apr 30. Epub 2020 Apr 30.

Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.

With licensure of extended half-life (EHL) factor products and the changing landscape of available hemophilia products, patients and providers have options for less treatment-intense prophylaxis. The impact of these products in clinical practice to date remains understudied. We aimed to quantify the use of EHL products in prophylaxis in the US using the ATHNdataset, a database of 145 ATHN-affiliated hemophilia treatment centers (HTCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25844DOI Listing

From Hematologist's desk: The effect of COVID-19 on the blood system.

Am J Hematol 2020 May 1. Epub 2020 May 1.

Division of Hematology and Oncology, Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, 01608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25849DOI Listing

Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.

Am J Hematol 2020 Apr 29. Epub 2020 Apr 29.

Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening immune-mediated thrombotic microangiopathy. Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have strikingly improved the outcome of this disease, however the rate of disease recurrence remains high. Specific predictors of relapse in patients in remission can be relevant for an optimal patient management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25845DOI Listing

Ecarin based coagulation testing.

Am J Hematol 2020 Apr 29. Epub 2020 Apr 29.

QUALIblood sa, Namur, Belgium.

Ecarin is derived from venom of Echis carinatus, and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described for decades, but these assays were typically restricted to reference or speciality coagulation laboratories. This test was initially described for the assessment of direct thrombin inhibitors (eg, bivalirudin lepirudin, or argatroban) and was not affected by heparins or heparinoids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25852DOI Listing

Role of imaging in multiple myeloma.

Am J Hematol 2020 Apr 29. Epub 2020 Apr 29.

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25846DOI Listing

Hematologic parameters in patients with COVID-19 infection: a reply.

Am J Hematol 2020 Apr 27. Epub 2020 Apr 27.

Department of Haematology, Tan Tock Seng Hospital, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25847DOI Listing

Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder, characterized by complement-mediated intravascular hemolysis and thrombosis. The increased incidence of PNH-driven thrombosis is still poorly understood, but unlike other thrombotic disorders, is thought to largely occur through complement-mediated mechanisms. Treatment with a C5 inhibitor, eculizumab, has been shown to significantly reduce the number of thromboembolic events in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25841DOI Listing

Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Hematologic Malignancies and Stem Cell Transplant Program, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.

Venous thromboembolic events (VTE) are a frequent complication of lymphoma. We conducted a retrospective analysis to compare VTE risk in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Subjects were randomly assigned to training and validation sets to identify risk factors of VTE and evaluate risk model performance, including the Khorana score. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25837DOI Listing

A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Centre for Haematology, St Mary's Hospital campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25842DOI Listing

Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Acute graft-vs-host disease (aGVHD) is one of the most important causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly for those with steroid-refractory (SR)-aGVHD. We aimed to identify the prognostic factors and long-term clinical outcomes of basiliximab treatment for SR-aGVHD. Basiliximab was administered on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II, or patients showed no response after four doses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25839DOI Listing

A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compared two salvage regimens; mitoxantrone, etoposide, and cytarabine (MEC) and mitoxantrone and high-dose Ara-C (Ara-C couplets). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25838DOI Listing
April 2020
3.798 Impact Factor

Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.

Authors:
Gary W Moore

Am J Hematol 2020 Apr 20. Epub 2020 Apr 20.

Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, UK.

Lupus anticoagulants (LA) are heterogeneous antibodies and no single assay will detect every LA. Consequently, testing is commonly undertaken with both dilute Russell's viper venom time (dRVVT) and LA-responsive activated partial thromboplastin time (aPTT) to maximize detection rates. Although a huge body of evidence attests to the diagnostic utility of these assays, they have limitations that can render them unreliable in certain circumstances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25836DOI Listing